Targeting a protein called LTBP1 may help overcome chemotherapy resistance and improve outcomes for patients with advanced bladder cancer, according to research published recently in Scientific Reports.
Cisplatin-based chemotherapy remains the standard treatment for advanced bladder cancer, yet many patients eventually stop responding. This study highlights LTBP1 as a key factor behind that resistance, offering a possible path to make treatment more effective.
Researchers analyzed tumor samples from patients who had not yet received cisplatin and those whose cancer had become resistant. They identified 828 differentially expressed proteins, including 513 that were increased and 315 that were decreased in resistant tumors. These proteins were linked to processes such as immune activity, cell movement and signaling pathways known to influence cancer spread and survival.
By combining multiple datasets, including GEO and TCGA, investigators narrowed their focus to 85 genes associated with resistance. LTBP1 emerged as a central player. Higher levels of LTBP1 were linked to more advanced disease stages and worse overall survival. Expression of this protein also increased as tumors progressed, suggesting it may actively drive cancer growth and aggressiveness.
“LTBP1 expression was found to correlate with poor clinical prognosis in bladder cancer patients,” explained the authors of this research.
Read more about the prognosis of bladder cancer
Laboratory experiments showed that reducing LTBP1 levels in bladder cancer cells slowed their growth, movement and ability to invade other tissues. This effect appeared to work through the TGF-β pathway, which is known to promote epithelial-mesenchymal transition, a process that helps cancer spread. When LTBP1 was suppressed, cancer cells became less aggressive and more vulnerable.
Importantly, blocking LTBP1 also made chemotherapy more effective. Cells with reduced LTBP1 had lower IC50 values for cisplatin, meaning smaller doses were needed to kill them. These cells were also more likely to undergo apoptosis, which is programmed cell death, especially when treated with cisplatin. In mouse models, combining LTBP1 inhibition with cisplatin led to the smallest tumors and the fewest lung metastases, without clear added toxicity.
For patients, these findings suggest that future treatments targeting LTBP1 could help overcome one of the biggest challenges in bladder cancer care: resistance to chemotherapy. While more research and clinical trials are needed, this approach could eventually lead to more personalized therapies that improve response rates, slow disease progression and extend survival.
Sign up here to get the latest news, perspectives, and information about bladder cancer sent directly to your inbox. Registration is free and only takes a minute.